Similar results have been obtained with the concurrent (but not sequential) delivery of ICD-inducing chemotherapeutics or fractionated RT and an ICI targeting PD-L1 in preclinical models of CRC (CT26), triple-negative breast cancer (TNBC) (4T1) and glioblastoma [26, 65]. Here, CD274 is linked to glioblastoma.